Presentation is loading. Please wait.

Presentation is loading. Please wait.

CEGEDIM © copyright 2007 – this document should not be distributed without CEGEDIM authorisation.

Similar presentations


Presentation on theme: "CEGEDIM © copyright 2007 – this document should not be distributed without CEGEDIM authorisation."— Presentation transcript:

1 CEGEDIM © copyright 2007 – this document should not be distributed without CEGEDIM authorisation

2 CHARAKTERISTIKA STUDIE TOPIC: Treatment of patients with diarrhoea, Smecta. TIME OF RESEARCH: October-November 2007 TARGET GROUP: pediatrics SAMPLING POINTS: whole Czech Republic METHODOLOGY: face to face interviewing SAMPLING METHOD: stratified random sampling SOURCE OF ADDRESSES: Cegedim Strategic Data TOTAL NUMBER OF QUESTIONNAIRES: 98 QUESTIONNAIRE: prepared by Cegedim Strategic Data on the assignment of Ipsen PROJECT MANAGER, DATA ANALASIS: Dan Hrdlička Lukáš Pertl

3 Cegedim CZ, Cegedim Strategic Data 2007 Q. 1: Will you estimate how many patients with diarrhoea do you monthly meet in your practice on the average. Ipsen – Medibus PED4 average number of patients per monthmedian – the middle value (base for average – total sample) N TOT = 98, N LC = 36, N MC = 39, N BC = 23

4 Cegedim CZ, Cegedim Strategic Data 2007 Q. 2: Which preparation is usually your first choice anti-diarrhoeal? (the most often named) (% base – total sample) N TOTAL = 98, N LC = 36, N MC = 39, N BC = 23 Ipsen – Medibus PED4 TOTAL LITTLE CITY MIDDLE CITY BIG CITY

5 Cegedim CZ, Cegedim Strategic Data 2007 Q. 3A: Why is Smecta your first choice anti-diarrhoeal? Which are its main advantages, strong points? (most often named) (% base – Smecta is first choice anti-diarrhoeal) N TOTAL = 64 Ipsen – Medibus PED4

6 Cegedim CZ, Cegedim Strategic Data 2007 Q. 3B: Why is Hylak your first choice anti-diarrhoeal? Which are its main advantages, strong points? (most often named) (% base – Hylak is first choice anti-diarrhoeal) N TOTAL = 27 Ipsen – Medibus PED4

7 Cegedim CZ, Cegedim Strategic Data 2007 Ipsen – Medibus PED4 Q. 4: Do you currently prescribe or recommend to your patients also Smecta? (% base – total sample) N TOT = 98 yes, I prescribe / I recommend I do not prescribe / I do not recommend

8 Cegedim CZ, Cegedim Strategic Data 2007 Q. 5: What are your main reasons to prescribe/recommend Smecta. (most often named) (% base – Smecta is first choice anti-diarrhoeal) N TOTAL = 98 GlaxoSmithKline – Medibus PED4

9 Cegedim CZ, Cegedim Strategic Data 2007 Q. 6A: Will you estimate how many patients with diarrhoea do you monthly prescribe with Smecta on the average. Ipsen – Medibus PED4 average number of patients per monthmedian – the middle value (base for average – total sample) N TOT = 98, N LC = 36, N MC = 39, N BC = 23

10 Cegedim CZ, Cegedim Strategic Data 2007 Q. 6B: Will you estimate to how many patients with diarrhoea do you monthly recommend Smecta on the average. Ipsen – Medibus PED4 average number of patients per monthmedian – the middle value (base for average – total sample) N TOT = 98, N BC = 36, N MC = 39, N BC = 23

11 Cegedim CZ, Cegedim Strategic Data 2007 Ipsen – Medibus PED4 Analysis II. q. 6: Rate of prescription and recommendation of Smecta. (% base – total sample) N TOT = 98, N BC = 36, N MC = 39, N BC = 23 Smecta - total

12 Cegedim CZ, Cegedim Strategic Data 2007 Ipsen – Medibus PED4 Analysis II. q. 6: Rate of prescription and recommendation of Smecta. (% base – total sample) Smecta - prescribing Smecta - recommending TOTAL (N = 98) LITTLE CITY (N = 36) MIDDLE CITY (N = 39) BIG CITY (N = 23)

13 Cegedim CZ, Cegedim Strategic Data 2007 Ipsen – Medibus PED4 Q. 7A: Will you estimate at which % of patients using Smecta do you continue with treatment with other preparations – e.g. with probiotics and at which % of patients you do not continue with additional treatment. (base for average % - total sample) I continue with additional treatment I do not continue with additional treatment TOTAL (N = 98) LITTLE CITY (N = 36) MIDDLE CITY (N = 39) BIG CITY (N = 23)

14 Cegedim CZ, Cegedim Strategic Data 2007 Q. 7B: If you continue with additional treatment at patients using Smecta, which particular preparations do you prescribe/recommend after Smecta? (the most often named) (% base – continue with treatment with other preparations) N TOTAL = 90 Ipsen – Medibus PED4

15 Cegedim CZ, Cegedim Strategic Data 2007 Q. 8A: Try please to specify – when, at which cases, at what kind of patients do you use Smecta. (most often named) (% base – total sample) N TOTAL = 98 Ipsen – Medibus PED4

16 Cegedim CZ, Cegedim Strategic Data 2007 Q. 8B: Try please to specify – when, at which cases, at what kind of patients do you use probiotics. (most often named) (% base – total sample) N TOTAL = 98 Ipsen – Medibus PED4

17 Cegedim CZ, Cegedim Strategic Data 2007 Q. 9A: How do you usually solve rotavirus infections? (most often named) (% base – total sample) N TOTAL = 98 Ipsen – Medibus PED4

18 Cegedim CZ, Cegedim Strategic Data 2007 Q. 9B: If you prescribe your patients with rotavirus infections with pharmacological treatment, which preparations do you most often use? (most often named) (% base – total sample) N TOTAL = 98 Ipsen – Medibus PED4


Download ppt "CEGEDIM © copyright 2007 – this document should not be distributed without CEGEDIM authorisation."

Similar presentations


Ads by Google